Who Paid My Doc
Lina Amini
Ophthalmic Plastic and Reconstructive Surgery Chula Vista, CA Medical Doctor
NPI 1063625374 CMS profile 184652
1400 E Palomar St, Chula Vista, CA 91913
General payments
$362
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Lina Amini of Chula Vista, CA is reported in the CMS Open Payments database as having received $362 across 11 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 18th percentile of Ophthalmic Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $209 | 4 | |
| 2024 | General | $25 | 1 | |
| 2023 | General | $18 | 1 | |
| 2022 | General | $25 | 1 | |
| 2021 | General | $24 | 1 | |
| 2020 | General | $49 | 2 | |
| 2019 | General | $13 | 1 |
Beside peers
- Lina Amini
- Ophthalmic Plastic and Reconstructive Surgery median
- Middle half of Ophthalmic Plastic and Reconstructive Surgery
- National median
In program year 2025, general payments to Lina Amini were reported at $209. Among 325 Ophthalmic Plastic and Reconstructive Surgery profiles paid that year, the median was $298 and the middle half received between $132 and $820.
Show as a table
| Year | Lina Amini | Ophthalmic Plastic and Reconstructive Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13 | $182 | $73–$467 | $163 |
| 2020 | $49 | $125 | $41–$412 | $114 |
| 2021 | $24 | $173 | $52–$538 | $132 |
| 2022 | $25 | $237 | $78–$809 | $149 |
| 2023 | $18 | $291 | $103–$776 | $160 |
| 2024 | $25 | $304 | $108–$822 | $164 |
| 2025 | $209 | $298 | $132–$820 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 26 drugsPart D claims
3,273
Drug cost
$434,512
Branded share of claims
43.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lumigan Bimatoprost | Brand | 303 | $150,514 | |
| Rhopressa Netarsudil Mesylate | Brand | 127 | $59,575 | |
| Alphagan P Brimonidine Tartrate | Brand | 95 | $40,006 | |
| Combigan Brimonidine Tartrate/Timolol | Brand | 62 | $32,249 | |
| Vyzulta Latanoprostene Bunod | Brand | 74 | $29,556 | |
| Azopt Brinzolamide | Brand | 28 | $20,616 | |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | Brand | 130 | $16,444 | |
| Restasis Cyclosporine | Brand | 11 | $12,952 | |
| Travoprost | Generic | 133 | $11,501 | |
| Brinzolamide | Generic | 69 | $8,829 |
The 10 drugs with the highest cost, of 26 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$76,578
Medicare patients
242
Services billed
943
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 39% | |
| Arthritis | 36% | |
| Chronic kidney disease | 25% | |
| Ischemic heart disease | 23% | |
| Heart failure | 18% | |
| Atrial fibrillation | 17% | |
| Depression | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Ophthalmic Plastic and Reconstructive Surgery in California
Marjan Farid
Ophthalmic Plastic and Reconstructive Surgery · Irvine, CA
Jeffrey Joseph
Ophthalmic Plastic and Reconstructive Surgery · Newport Beach, CA
Sandy Zhang-Nunes
Ophthalmic Plastic and Reconstructive Surgery · Los Angeles, CA
Soheab Ugradar
Ophthalmic Plastic and Reconstructive Surgery · Los Angeles, CA
Andrea Kossler
Ophthalmic Plastic and Reconstructive Surgery · Stanford, CA
Nicolas Biro
Ophthalmic Plastic and Reconstructive Surgery · West Covina, CA
Related records
Ophthalmic Plastic and Reconstructive Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Ophthalmic Plastic and Reconstructive Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.